CINCINNATI, June 02, 2016 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of the MyTaq™ Plant-PCR Kit, the latest in the line of kits from Bioline for direct PCR. The MyTaq™ Plant-PCR Kit is the first of many products Bioline is bringing to the agricultural market to advance plant genetic research. Bioline is also developing new technologies to support Agribio companies in their quest to improve agriculturally important plants.
MyTaq™ Plant-PCR Kit offers fast, highly-specific, direct PCR from a wide range of plant leaf samples. The novel buffer system is highly tolerant to PCR inhibitors typically present in plant samples and so circumvents the need for traditional, time-consuming extraction steps or additional PCR stabilizers. As a result, in a single tube with a pre-optimized protocol, the MyTaq™ Plant-PCR Kit delivers significantly improved assay sensitivity and reproducibility over competitors’ kits. The MyTaq™ Plant-PCR Kit protocol is therefore easy to automate making it ideal for high-throughput applications, such as genotyping and transgenic screening.
Marco Calzavara, President of Bioline commented, “With the MyTaq™ Plant-PCR Kit, researchers can now quickly achieve the purity and yield necessary for high-performance PCR from plant tissues. This makes MyTaq™ Plant-PCR Kit the perfect addition to our expanding portfolio of direct PCR reagents.”
Richard L. Eberly, President of Meridian Life Science, Inc., stated, “We are delighted to release the MyTaq™ Plant-PCR Kit, which simplifies the process of PCR from plant tissues. We are committed to our life science customers and to bringing innovation and quality products; such as the MyTaq™ Plant-PCR Kit to the research laboratory and Agribio companies.”
ABOUT MERIDIAN BIOSCIENCE, INC.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and biotech companies in more than 70 countries around the world. The Company’s shares are traded on NASDAQ’s Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
For more information about Bioline, please visit www.bioline.com
For more information about Meridian Life Science, Inc., please visit www.meridianlifescience.com
For more information about Meridian Bioscience, Inc., please visit www.meridianbioscience.com
Richard L. Eberly, email@example.com
Richard L. Eberly
Meridian Bioscience, Inc.